The Australian Competition and Consumer Commission (ACCC) has listed itsconcerns over global healthcare giant Zoetis’ proposed acquisition of Hunter-based Jurox.

In Australia, the companies are two of the largest suppliers of variousprescription and over-the-counter products for production animals andcompanion animals.

In a statement of issues, the ACCC said that the proposed acquisition wouldremove one of Zoetis’ closest competitors in the supply of intramammaryantibiotics for lactating cows, intramammary antibiotics for dry cows, andteat sealants for cows in Australia.

In the event of acquisition, the ACCC is concerned Zoetis would have no closecompetitors and in turn will likely lead to higher prices in each market.

Another area of concern for the ACCC is that by acquiring Jurox, Zoetis willcontrol two of the three sheep parasiticides that are most effective atmanaging parasiticide resistance, again likely leading to higher prices inthis market.

The ACCC is currently seeking submissions based on the statement of issuesraised. Submissions must be submitted by 11 March 2022, with a final decisionlikely on 28 April 2022.

Tagged: Jurox, Zoetis

Previous PetLab donates $150,000 of products to animal shelter

Next Nestlé Purina records double digit growth